Matches in SemOpenAlex for { <https://semopenalex.org/work/W42504781> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W42504781 endingPage "97" @default.
- W42504781 startingPage "888" @default.
- W42504781 abstract "Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II, multicenter, open-label study evaluated the efficacy, tolerability, and pharmacodynamics of apremilast in patients with recalcitrant plaque psoriasis.<BR>This multicenter, open-label study comprised four phases: pre-treatment (≤35 days), treatment (12 weeks), extension (12 weeks), and observational follow-up (4 weeks). Patients with recalcitrant plaque psoriasis received apremilast 20 mg BID for 12 weeks. Responders (≥75% improvement in Psoriasis Area and Severity Index [PASI-75]) continued treatment and non-responders (< PASI-75) were titrated to apremilast 30 mg BID through week 24. Efficacy assessments included change in static Physician's Global Assessment, PASI, and body surface area, and proportion of patients achieving PASI-50, PASI-75, and PASI-90. Other assessments included adverse events, lesional skin biopsies to assess changes in epidermal thickness, and immunohistochemistry to assess changes in peripheral blood subsets.A total of 30 patients were enrolled. At week 12, 67% of patients had a ≥1-point improvement in static Physician's Global Assessment, meeting treatment effect criterion. Mean percent decreases (improvements) from baseline were -59% for PASI score and -53% for body surface area. Most adverse events were mild. Median reduction in epidermal thickness was 34% at week 12 (P=0.083); five patients showed absence of keratin 16. Significant reductions in CD11c, CD3, and CD56 indicate that apremilast reduced myeloid dendritic cell, T-cell, and NK-cell or NK-T-cell infiltration into the epidermis and dermis. Reduced inflammatory leukocytes, with a pattern of broad, partial inhibition, suggested reduced IL-23/Th17 and Th22 response pathways.These results confirm apremilast's biological and clinical activity and support ongoing studies in psoriasis. Clinicaltrials.gov Identifier: NCT00521339." @default.
- W42504781 created "2016-06-24" @default.
- W42504781 creator A5003710463 @default.
- W42504781 creator A5017572254 @default.
- W42504781 creator A5018577996 @default.
- W42504781 creator A5037836846 @default.
- W42504781 creator A5049859852 @default.
- W42504781 creator A5058924958 @default.
- W42504781 creator A5075798284 @default.
- W42504781 creator A5080337749 @default.
- W42504781 date "2013-08-01" @default.
- W42504781 modified "2023-09-30" @default.
- W42504781 title "Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study." @default.
- W42504781 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23986162" @default.
- W42504781 hasPublicationYear "2013" @default.
- W42504781 type Work @default.
- W42504781 sameAs 42504781 @default.
- W42504781 citedByCount "31" @default.
- W42504781 countsByYear W425047812014 @default.
- W42504781 countsByYear W425047812015 @default.
- W42504781 countsByYear W425047812016 @default.
- W42504781 countsByYear W425047812017 @default.
- W42504781 countsByYear W425047812019 @default.
- W42504781 countsByYear W425047812020 @default.
- W42504781 countsByYear W425047812021 @default.
- W42504781 countsByYear W425047812022 @default.
- W42504781 countsByYear W425047812023 @default.
- W42504781 crossrefType "journal-article" @default.
- W42504781 hasAuthorship W42504781A5003710463 @default.
- W42504781 hasAuthorship W42504781A5017572254 @default.
- W42504781 hasAuthorship W42504781A5018577996 @default.
- W42504781 hasAuthorship W42504781A5037836846 @default.
- W42504781 hasAuthorship W42504781A5049859852 @default.
- W42504781 hasAuthorship W42504781A5058924958 @default.
- W42504781 hasAuthorship W42504781A5075798284 @default.
- W42504781 hasAuthorship W42504781A5080337749 @default.
- W42504781 hasConcept C126322002 @default.
- W42504781 hasConcept C16005928 @default.
- W42504781 hasConcept C197934379 @default.
- W42504781 hasConcept C2776173921 @default.
- W42504781 hasConcept C2776260265 @default.
- W42504781 hasConcept C2777011040 @default.
- W42504781 hasConcept C2777501473 @default.
- W42504781 hasConcept C2778375690 @default.
- W42504781 hasConcept C2780564577 @default.
- W42504781 hasConcept C2781427535 @default.
- W42504781 hasConcept C71924100 @default.
- W42504781 hasConcept C90924648 @default.
- W42504781 hasConcept C98274493 @default.
- W42504781 hasConceptScore W42504781C126322002 @default.
- W42504781 hasConceptScore W42504781C16005928 @default.
- W42504781 hasConceptScore W42504781C197934379 @default.
- W42504781 hasConceptScore W42504781C2776173921 @default.
- W42504781 hasConceptScore W42504781C2776260265 @default.
- W42504781 hasConceptScore W42504781C2777011040 @default.
- W42504781 hasConceptScore W42504781C2777501473 @default.
- W42504781 hasConceptScore W42504781C2778375690 @default.
- W42504781 hasConceptScore W42504781C2780564577 @default.
- W42504781 hasConceptScore W42504781C2781427535 @default.
- W42504781 hasConceptScore W42504781C71924100 @default.
- W42504781 hasConceptScore W42504781C90924648 @default.
- W42504781 hasConceptScore W42504781C98274493 @default.
- W42504781 hasIssue "8" @default.
- W42504781 hasLocation W425047811 @default.
- W42504781 hasOpenAccess W42504781 @default.
- W42504781 hasPrimaryLocation W425047811 @default.
- W42504781 hasRelatedWork W2036756704 @default.
- W42504781 hasRelatedWork W2415983218 @default.
- W42504781 hasRelatedWork W2602145888 @default.
- W42504781 hasRelatedWork W2753520953 @default.
- W42504781 hasRelatedWork W3163607041 @default.
- W42504781 hasRelatedWork W3171835438 @default.
- W42504781 hasRelatedWork W3195950964 @default.
- W42504781 hasRelatedWork W4200190673 @default.
- W42504781 hasRelatedWork W4224225049 @default.
- W42504781 hasRelatedWork W42504781 @default.
- W42504781 hasVolume "12" @default.
- W42504781 isParatext "false" @default.
- W42504781 isRetracted "false" @default.
- W42504781 magId "42504781" @default.
- W42504781 workType "article" @default.